NEW YORK GENOME CENTER INC: Form 990, tax year 2022

View the entire original 990 at ProPublica ↗

Organization: NEW YORK GENOME CENTER INC (EIN 80-0631734)
Tax period: 2022-01-01 to 2022-12-31
Filed: 2023-11-15
IRS object ID: 202303199349311290
Schema version: 2022v5.0
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule I
Schedule J
Schedule L
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2023-11-15T12:09:59-06:00	ReturnTs
Tax Period End	2022-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	135565207	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	KPMG LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	345 PARK AVENUE	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	101540102	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2022-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	800631734	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	NEW YORK GENOME CENTER INC	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	NEWY	BusinessNameControlTxt
Phone	6469777000	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVENUE OF THE AMERICAS FL 7	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100131941	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	MARIA JOANTA	PersonNm
Person Title	CHIEF FINANCIAL OFFICER	PersonTitleTxt
Phone	6469777000	PhoneNum
Signature	2023-11-14	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	MARIA	PersonFirstNm
Person Last	JOANTA	PersonLastNm

Field	Value	IRS element (for citing)
SSN	999009999	SSN

Field	Value	IRS element (for citing)
IRS Responsible Prty Info Curr	0	IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	EVAN W SEEKAMP	PreparerPersonNm
PTIN	P01907071	PTIN
Phone	2127589700	PhoneNum
Preparation	2023-11-14	PreparationDt

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

Field	Value	IRS element (for citing)
Trusted Customer	3	TrustedCustomerCd
Authentication Assurance Level	AAL1	AuthenticationAssuranceLevelCd
Identity Assurance Level	IAL1	IdentityAssuranceLevelCd

Field	Value	IRS element (for citing)
Tax	2022	TaxYr
Build TS	2023-04-26 12:10:37Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	TOM MANIATIS	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVE OF THE AMERICAS	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10013	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$72,179,367	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.NYGENOME.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	2010	FormationYr
Legal Domicile State	DE	LegalDomicileStateCd
Activity Or Mission	ADVANCING GENOMIC RESEARCH TO DRIVE NOVEL BIOMEDICAL DISCOVERIES TO IMPROVE HUMAN HEALTH.	ActivityOrMissionDesc
Voting Members Governing Body	24	VotingMembersGoverningBodyCnt
Voting Members Independent	23	VotingMembersIndependentCnt
Total Employee	240	TotalEmployeeCnt
Total Volunteers	25	TotalVolunteersCnt
Total Gross UBI	$1,946,211	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$61,556,925	PYContributionsGrantsAmt
CY Contributions Grants	$53,970,524	CYContributionsGrantsAmt
PY Program Service Revenue	$9,002,608	PYProgramServiceRevenueAmt
CY Program Service Revenue	$11,277,968	CYProgramServiceRevenueAmt
PY Investment Income	$27,107	PYInvestmentIncomeAmt
CY Investment Income	-$12,410	CYInvestmentIncomeAmt
PY Other Revenue	$1,712,471	PYOtherRevenueAmt
CY Other Revenue	$2,665,604	CYOtherRevenueAmt
PY Total Revenue	$72,299,111	PYTotalRevenueAmt
CY Total Revenue	$67,901,686	CYTotalRevenueAmt
PY Grants And Similar Paid	$1,760,070	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$2,253,429	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$27,400,508	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$29,302,214	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$250	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$140	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$905,356	CYTotalFundraisingExpenseAmt
PY Other Expenses	$39,947,593	PYOtherExpensesAmt
CY Other Expenses	$40,640,090	CYOtherExpensesAmt
PY Total Expenses	$69,108,421	PYTotalExpensesAmt
CY Total Expenses	$72,195,873	CYTotalExpensesAmt
PY Revenues Less Expenses	$3,190,690	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$4,294,187	CYRevenuesLessExpensesAmt
Total Assets BOY	$85,222,125	TotalAssetsBOYAmt
Total Assets EOY	$181,740,451	TotalAssetsEOYAmt
Total Liabilities BOY	$46,079,469	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$146,891,982	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$39,142,656	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$34,848,469	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	OPERATE A STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$53,435,617	ExpenseAmt
Grant	$2,253,429	GrantAmt
Revenue	$9,825,238	RevenueAmt
Desc	GENOME SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SEVEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 86,900 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE THOUSANDS OF GENOMES A YEAR. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$5,438,939	ExpenseAmt
Revenue	$1,452,730	RevenueAmt
Desc	CLINICAL SEQUENCING: NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLEGENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, AND THE SMASH GENOMIC ASSAY.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$58,874,556	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	0	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	Yes (1)	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (1)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	0	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	Yes (1)	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	Yes (1)	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	0	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	Yes (1)	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	0	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	63	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	240	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (1)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (1)	Form990TFiledInd
Foreign Financial Account	0	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	0	QuidProQuoContributionsInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	24	GoverningBodyVotingMembersCnt
Independent Voting Member	23	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	Yes (1)	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	Yes (1)	MembersOrStockholdersInd
Election Of Board Members	Yes (1)	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	LA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Other Website	Yes (X)	OtherWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	NANCY KONG	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	6469777154	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVENUE OF THE AMERICAS 7TH FL	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10013	ZIPCd

Field	Value	IRS element (for citing)
Info In Schedule O Part VII	Yes (X)	InfoInScheduleOPartVIIInd

Form990 Part VII Section A Form990PartVIISectionAGrp (39 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
RUSSELL L CARSON MBA
DIRECTOR & CHAIRMAN	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
IVAN G SEIDENBERG MBA
DIRECTOR & CO-CHAIR	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
HERB PARDES MD
DIRECTOR & EXEC. VICE CHAIR	1.00	0.00	Yes (X)		$0	$0	$0
GORDON F TOMASELLI MD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
BRUCE STILLMAN PHD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
ANIL RUSTGI MD
DIRECTOR (THRU 03/22)	1.00	0.00	Yes (X)		$0	$0	$0
KATRINA ARMSTRONG MD
DIRECTOR (AS OF 03/22)	1.00	0.00	Yes (X)		$0	$0	$0
CRAIG B THOMPSON MD
DIRECTOR (THRU 10/22)	1.00	0.00	Yes (X)		$0	$0	$0
SELWYN VICKERS MD
DIRECTOR (AS OF 10/22)	1.00	0.00	Yes (X)		$0	$0	$0
DENNIS S CHARNEY MD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
DAFNA BAR-SAGI PHD
SENIOR VP, CHIEF SCIENTIFIC OFFICER	1.00	0.00	Yes (X)		$0	$0	$0
KEVIN J TRACEY MD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
KENNETH A DILL PHD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
RICHARD P LIFTON MD PHD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
AUGUSTINE M K CHOI MD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
ELI CASDIN
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
NICHOLAS DONOFRIO
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
JOSEPH E EDELMAN
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
JOHN B EHRENKRANZ
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
ANTHONY B EVNIN PHD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
JOHN P HAVENS
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
WESLIE R JANEWAY
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
FRANK V SICA
DIRECTOR & COMMITTEE CHAIR	1.00	0.00	Yes (X)		$0	$0	$0
JIM SIMONS PHD
DIRECTOR	1.00	0.00	Yes (X)		$0	$0	$0
NANCY THORNBERRY
DIRECTOR (AS OF 10/22)	1.00	0.00	Yes (X)		$0	$0	$0
TOM MANIATIS PHD
SCIENTIFIC DIRECTOR & CEO	40.00	0.00	Yes (X)	Yes (X)	$633,696	$0	$0
ELIZABETH BROOKS O'BRIEN
VP & GENERAL COUNSEL	40.00	0.00		Yes (X)	$453,705	$0	$41,087
MARIA JOANTA
CHIEF FINANCIAL OFFICER	40.00	0.00		Yes (X)	$365,440	$0	$47,560
CAROL ASHE
CHIEF BUSINESS OFFICER	40.00	0.00			$425,448	$0	$61,483	Yes (X)
CHARLES GAGNON
CHIEF INFORMATION OFFICER	40.00	0.00			$329,980	$0	$47,431	Yes (X)
THOMAS LEHNER
SCI DIR, NEURO DIS GEN	40.00	0.00			$394,617	$0	$38,366	Yes (X)
SOREN GERMER
SVP, GENOME TECHNOLOGIES	40.00	0.00			$424,568	$0	$35,406	Yes (X)
MICHAEL CHARLES ZODY
SCIENTIFIC DIR, COMP BIOLOGY	40.00	0.00			$350,538	$0	$27,331	Yes (X)
SARAH LESSER AVINS
SVP, ADVANCEMENT & CHIEF DEV. OFC.	40.00	0.00			$554,010	$0	$18,417	Yes (X)
SHAILAJA GARGEYA
SENIOR DIR, SOFTWARE ENGINEER	40.00	0.00			$320,347	$0	$18,312		Yes (X)
DAYNA M OSCHWALD
CHIEF OF STAFF	40.00	0.00			$268,319	$0	$35,681		Yes (X)
CHRISTOPHER PHIFER BLACK
SENIOR DIRECTOR, RESEARCH COMPUTING	40.00	0.00			$244,736	$0	$42,798		Yes (X)
HANNAH GOULDING
SENIOR DIRECTOR, HUMAN RESOURCES	40.00	0.00			$235,875	$0	$14,269		Yes (X)
JESSICA LEIGH LEITNER
SENIOR DIRECTOR, DEVELOPMENT	40.00	0.00			$227,847	$0	$21,817		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$5,229,126	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$449,958	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	79	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt	Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt	CityContractorAddress/ForeignAddress/CityNm	CountryContractorAddress/ForeignAddress/CountryCd	Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd
DONNELLY MECHANICAL
96-59 222ND STREET	QUEENS	NY	11429	ENGINEERING SERVICES	$758,802
GUARDIAN SERVICES INDUSTRIES INC
88005 EXPEDITE WAY	CHICAGO	IL	60695	CLEANING SERVICES	$365,998
STONECOURT 365 HOLDINGS LLC
200 CONNECTICUT AVENUE SUITE 5A	NORWALK	CT	06854	DATA SERVICES	$231,313
KPMG LLP
PO BOX 120511	DALLAS	TX	75312	ACCOUNTING SERVICES	$164,350
WAYNE CLARKE
				CONSULTING SERVICES	$149,042	327 3D ST E SASKATOON	SASKATCHEWAN	CA	S7H 1L4

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	51	CntrctRcvdGreaterThan100KCnt
Membership Dues	$2,735,000	MembershipDuesAmt
Government Grants	$14,946,320	GovernmentGrantsAmt
All Other Contributions	$36,289,204	AllOtherContributionsAmt
Noncash Contributions	$2,153,885	NoncashContributionsAmt
Total Contributions	$53,970,524	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt
RESEARCH SEQUENCING	541700	$9,825,238	$7,879,027	$1,946,211
CLINICAL SEQUENCING	541700	$1,452,730	$1,452,730

Field	Value	IRS element (for citing)
Total Program Service Revenue	$11,277,968	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$12,410	TotalRevenueColumnAmt
Exclusion	-$12,410	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$2,073,162	TotalRevenueColumnAmt
Exclusion	$2,073,162	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$4,115,198	RealAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$4,277,681	RealAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	-$162,483	RealAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$162,483	TotalRevenueColumnAmt
Exclusion	-$162,483	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	ExclusionExclusionAmt
EDC LOAN RECOGNITION	900099	$526,245	$526,245
OTHER REVENUE	900099	$228,680	$228,680

Field	Value	IRS element (for citing)
Other Revenue Total	$754,925	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$67,901,686	TotalRevenueColumnAmt
Related Or Exempt Func Income	$9,331,757	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$1,946,211	UnrelatedBusinessRevenueAmt
Exclusion	$2,653,194	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$2,148,906	TotalAmt
Program Services	$2,148,906	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$104,523	TotalAmt
Program Services	$104,523	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$4,231,643	TotalAmt
Program Services	$1,883,139	ProgramServicesAmt
Management And General	$1,776,077	ManagementAndGeneralAmt
Fundraising	$572,427	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$19,467,399	TotalAmt
Program Services	$14,947,954	ProgramServicesAmt
Management And General	$4,308,872	ManagementAndGeneralAmt
Fundraising	$210,573	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$1,191,827	TotalAmt
Program Services	$887,950	ProgramServicesAmt
Management And General	$271,721	ManagementAndGeneralAmt
Fundraising	$32,156	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$2,286,655	TotalAmt
Program Services	$1,788,690	ProgramServicesAmt
Management And General	$491,800	ManagementAndGeneralAmt
Fundraising	$6,165	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$2,124,690	TotalAmt
Program Services	$1,609,600	ProgramServicesAmt
Management And General	$499,133	ManagementAndGeneralAmt
Fundraising	$15,957	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$293,528	TotalAmt
Management And General	$293,528	ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$164,600	TotalAmt
Management And General	$164,600	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$60,453	TotalAmt
Management And General	$60,453	ManagementAndGeneralAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$140	TotalAmt
Fundraising	$140	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$2,906,160	TotalAmt
Program Services	$2,688,760	ProgramServicesAmt
Management And General	$217,400	ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$418,019	TotalAmt
Program Services	$102,382	ProgramServicesAmt
Management And General	$313,992	ManagementAndGeneralAmt
Fundraising	$1,645	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$3,039,096	TotalAmt
Program Services	$2,654,651	ProgramServicesAmt
Management And General	$383,161	ManagementAndGeneralAmt
Fundraising	$1,284	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$402,373	TotalAmt
Program Services	$402,373	ProgramServicesAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$13,493,554	TotalAmt
Program Services	$11,382,264	ProgramServicesAmt
Management And General	$2,075,998	ManagementAndGeneralAmt
Fundraising	$35,292	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$276,349	TotalAmt
Program Services	$264,043	ProgramServicesAmt
Management And General	$12,171	ManagementAndGeneralAmt
Fundraising	$135	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$97,094	TotalAmt
Program Services	$77,562	ProgramServicesAmt
Management And General	$18,295	ManagementAndGeneralAmt
Fundraising	$1,237	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$301,313	TotalAmt
Program Services	$165,081	ProgramServicesAmt
Management And General	$134,958	ManagementAndGeneralAmt
Fundraising	$1,274	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$5,179,168	TotalAmt
Program Services	$4,834,587	ProgramServicesAmt
Management And General	$325,700	ManagementAndGeneralAmt
Fundraising	$18,881	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$660,470	TotalAmt
Management And General	$660,470	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (3 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt
DIRECT COST OF SEQUENCI	$10,048,800	$10,048,800
RESEARCH	$2,755,732	$2,755,732
RECRUITMENT	$74,048	$11,862	$62,186

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$469,333	TotalAmt
Program Services	$115,697	ProgramServicesAmt
Management And General	$345,446	ManagementAndGeneralAmt
Fundraising	$8,190	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$72,195,873	TotalAmt
Program Services	$58,874,556	ProgramServicesAmt
Management And General	$12,415,961	ManagementAndGeneralAmt
Fundraising	$905,356	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$10,264,308	BOYAmt
EOY	$15,599,937	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$7,859,130	BOYAmt
EOY	$8,022,270	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$6,350,857	BOYAmt
EOY	$5,451,902	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$2,423,898	BOYAmt
EOY	$2,260,088	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$3,304,280	BOYAmt
EOY	$3,583,624	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$134,621,258	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$90,760,203	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$47,467,089	BOYAmt
EOY	$43,861,055	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$7,552,563	BOYAmt
EOY	$102,961,575	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$85,222,125	BOYAmt
EOY	$181,740,451	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$5,032,047	BOYAmt
EOY	$7,934,093	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$12,695,217	BOYAmt
EOY	$15,840,681	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$4,100,000	BOYAmt
EOY	$3,380,000	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$24,252,205	BOYAmt
EOY	$119,737,208	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$46,079,469	BOYAmt
EOY	$146,891,982	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$26,513,021	BOYAmt
EOY	$22,710,365	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$12,629,635	BOYAmt
EOY	$12,138,104	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$39,142,656	BOYAmt
EOY	$34,848,469	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$85,222,125	BOYAmt
EOY	$181,740,451	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$4,294,187	ReconcilationRevenueExpnssAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$115,038,771	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$32,878,926	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$51,639,109	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$61,556,925	CurrentTaxYearMinus1YearAmt
Current Tax Year	$53,970,524	CurrentTaxYearAmt
Total	$315,084,255	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$115,038,771	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$32,878,926	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$51,639,109	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$61,556,925	CurrentTaxYearMinus1YearAmt
Current Tax Year	$53,970,524	CurrentTaxYearAmt
Total	$315,084,255	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$143,965,935	SubstantialContributorsTotAmt
Public Support Total170	$171,118,320	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$2,090,669	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$3,205,975	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$3,312,682	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$4,952,174	CurrentTaxYearMinus1YearAmt
Current Tax Year	$5,045,294	CurrentTaxYearAmt
Total	$18,606,794	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$104,653	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$38,049	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$742,082	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$258,491	CurrentTaxYearMinus1YearAmt
Current Tax Year	$19,731	CurrentTaxYearAmt
Total	$1,163,006	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$334,854,055	TotalSupportAmt
Gross Receipts Rltd Activities	$51,336,909	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.51100	PublicSupportCY170Pct
Public Support PY170	0.49720	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	0	VolunteersInd
Paid Staff Or Management	Yes (1)	PaidStaffOrManagementInd
Media Advertisements	0	MediaAdvertisementsInd
Mailings Members	0	MailingsMembersInd
Publications Or Broadcast	0	PublicationsOrBroadcastInd
Grants Other Organizations	0	GrantsOtherOrganizationsInd
Direct Contact Legislators	0	DirectContactLegislatorsInd
Rallies Demonstrations	0	RalliesDemonstrationsInd
Other Activities	Yes (1)	OtherActivitiesInd
Other Activities	$52,663	OtherActivitiesAmt
Total Lobbying Expenditures	$52,663	TotalLobbyingExpendituresAmt
Not Described Section501c3	0	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART II-B, LINE 1:	FormAndLineReferenceDesc
Explanation	THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. IN 2022, NYGC ENGAGED PAID LEGISLATIVE CONSULTANTS TO REPRESENT ITS INTERESTS AT THE STATE LEVEL. ADDITIONALLY, FROM TIME TO TIME, NYGC STAFF MAY CONTACT MEMBERS OF THE STATE LEGISLATURE AND EXECUTIVE BRANCH TO ENCOURAGE THEIR SUPPORT FOR NYGC. SUCH CONTACT MAY INCLUDE MEETINGS AND CORRESPONDENCE WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH THESE ACTIVITIES IN 2022 WAS 21,172. NYGC ALSO MAINTAINS MEMBERSHIPS IN IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE ACADEMIC MEDICAL RESEARCH COMMUNITY. IN 2022, $2,410 OF THE DUES THAT NYGC PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING.	ExplanationTxt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$71,120,415	OtherCostOrOtherBasisAmt
Depreciation	$30,385,592	DepreciationAmt
Book Value	$40,734,823	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$60,212,140	OtherCostOrOtherBasisAmt
Depreciation	$57,302,808	DepreciationAmt
Book Value	$2,909,332	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$3,288,703	OtherCostOrOtherBasisAmt
Depreciation	$3,071,803	DepreciationAmt
Book Value	$216,900	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$43,861,055	TotalBookValueLandBuildingsAmt

Other Assets Org OtherAssetsOrgGrp (3 entries)

DescDesc	Book ValueBookValueAmt
SECURITY DEPOSITS	$6,435,369
DEFERRED COMPENSATION	$217,995
OPERATING RIGHT OF USE ASSET	$96,308,211

Field	Value	IRS element (for citing)
Total Book Value Other Assets	$102,961,575	TotalBookValueOtherAssetsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

Field	Value	IRS element (for citing)
Desc	RIGHT OF USE LIABILITY	Desc
Amt	$119,737,208	Amt

Field	Value	IRS element (for citing)
Total Liability	$119,737,208	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$72,179,367	TotalRevEtcAuditedFinclStmtAmt
Revenue Not Reported	$0	RevenueNotReportedAmt
Revenue Subtotal	$72,179,367	RevenueSubtotalAmt
Other Revenues Not Included	-$4,277,681	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	-$4,277,681	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$67,901,686	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$76,473,554	TotExpnsEtcAuditedFinclStmtAmt
Other Expenses Included	$4,277,681	OtherExpensesIncludedAmt
Expenses Not Reported	$4,277,681	ExpensesNotReportedAmt
Expenses Subtotal	$72,195,873	ExpensesSubtotalAmt
Expenses Not Rpt Fincl Stmt	$0	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$72,195,873	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART X, LINE 2:	NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2022 AND 2021.
PART XI, LINE 4B - OTHER ADJUSTMENTS:	RECLASS OF DIRECT RENTAL EXPENSE -4,277,681.
PART XII, LINE 2D - OTHER ADJUSTMENTS:	RECLASS OF DIRECT RENTAL EXPENSE 4,277,681.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)

RegionRegionTxt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
EUROPE (INCLUDING ICELAND AND GREENLAND)	9	PROGRAM SERVICES	RESEARCH	$395,914
NORTH AMERICA	3	PROGRAM SERVICES	RESEARCH	$237,145
EAST ASIA AND THE PACIFIC	1	PROGRAM SERVICES	RESEARCH	$499

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	13	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	13	TotalEmployeeCnt
Subtotal Spent	$633,558	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$633,558	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp

Field	Value	IRS element (for citing)
Region	EUROPE (INCLUDING ICELAND AND GREENLAND)	RegionTxt
Purpose Of Grant	RESEARCH SUBAWARD	PurposeOfGrantTxt
Cash Grant	$16,760	CashGrantAmt
Manner Of Cash Disbursement	WIRE	MannerOfCashDisbursementTxt
Non Cash Assistance	$0	NonCashAssistanceAmt

Field	Value	IRS element (for citing)
Total501c3 Org	1	Total501c3OrgCnt

Foreign Individuals Grants ForeignIndividualsGrantsGrp

Field	Value	IRS element (for citing)
Type Of Assistance	RESEARCH	TypeOfAssistanceTxt
Region	NORTH AMERICA	RegionTxt
Recipient	1	RecipientCnt
Cash Grant	$87,763	CashGrantAmt
Manner Of Cash Disbursement	WIRE	MannerOfCashDisbursementTxt

Field	Value	IRS element (for citing)
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 2:	NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT.
PART I, LINE 3:	THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD.
PART III ACCOUNTING METHOD:

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (13 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Purpose Of GrantPurposeOfGrantTxt
COLUMBIA UNIVERSITY
615 WEST 131ST STREET	NEW YORK	NY	10027	135598093	501(C)(3)	$359,184	$0	RESEARCH SUBAWARD
JOHNS HOPKIN UNIVERSITY
3910 KESWICK ROAD	BALTIMORE	MD	21211	520595110	501(C)(3)	$258,161	$0	RESEARCH SUBAWARD
MEMORIAL SLOAN-KETTERING CANCER CENTER
1275 YORK AVENUE	NEW YORK	NY	10065	131924236	501(C)(3)	$246,134	$0	RESEARCH SUBAWARD
WEILL CORNELL MEDICAL COLLEGE
1300 YORK AVENUE	NEW YORK	NY	10065	150532082	501(C)(3)	$212,435	$0	RESEARCH SUBAWARD
NEW YORK UNIVERSITY
105 E 17TH STREET	NEW YORK	NY	10003	135562309	501(C)(3)	$199,783	$0	RESEARCH SUBAWARD
YALE UNIVERSITY
PO BOX 208356	NEW HAVEN	CT	06520	060646973	501(C)(3)	$172,656	$0	RESEARCH SUBAWARD
BROWN UNIVERSITY
PO BOX 1929	PROVIDENCE	RI	02912	050258809	501(C)(3)	$168,646	$0	RESEARCH SUBAWARD
COLD SPRING HARBOR LABORATORY
ONE BUNGTOWN ROAD	COLD SPRING HARBOR	NY	11724	112013303	501(C)(3)	$134,783	$0	RESEARCH SUBAWARD
EUROPEAN MOLECULAR BIOLOGY LABORATORY
1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	981291296	501(C)(3)	$110,920	$0	RESEARCH SUBAWARD
ROCKEFELLER UNIVERSITY
1230 YORK AVENUE	NEW YORK	NY	10065	131624158	501(C)(3)	$86,216	$0	RESEARCH SUBAWARD
NYU SCHOOL OF MEDICINE
105 E 17TH STREET	NEW YORK	NY	10003	135562308	501(C)(3)	$85,610	$0	RESEARCH SUBAWARD
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE	NEW YORK	NY	10029	136171197	501(C)(3)	$44,299	$0	RESEARCH SUBAWARD
THE REGENTS OF THE UNIVERISTY OF CALIFORNIA
9500 GILMAN DRIVE	MC LA JOLLA	CA	920930009	943067788	501(C)(3)	$30,000	$0	RESEARCH SUBAWARD

Field	Value	IRS element (for citing)
Total501c3 Org	13	Total501c3OrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Substantiation Required	Yes (1)	SubstantiationRequiredInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	0	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
TOM MANIATIS PHD
SCIENTIFIC DIRECTOR & CEO	$633,696	$0	$0	$0	$0	$0	$0	$0	$0	$0	$633,696	$0	$0	$0
SARAH LESSER AVINS
SVP, ADVANCEMENT & CHIEF DEV. OFC.	$554,010	$0	$0	$0	$0	$0	$18,300	$0	$117	$0	$572,427	$0	$0	$0
ELIZABETH BROOKS O'BRIEN
VP & GENERAL COUNSEL	$453,705	$0	$0	$0	$0	$0	$18,300	$0	$22,787	$0	$494,792	$0	$0	$0
CAROL ASHE
CHIEF BUSINESS OFFICER	$425,448	$0	$0	$0	$0	$0	$61,366	$0	$117	$0	$486,931	$0	$0	$0
SOREN GERMER
SVP, GENOME TECHNOLOGIES	$424,568	$0	$0	$0	$0	$0	$18,300	$0	$17,106	$0	$459,974	$0	$0	$0
THOMAS LEHNER
SCI DIR, NEURO DIS GEN	$394,617	$0	$0	$0	$0	$0	$25,525	$0	$12,841	$0	$432,983	$0	$0	$0
MARIA JOANTA
CHIEF FINANCIAL OFFICER	$365,440	$0	$0	$0	$0	$0	$18,300	$0	$29,260	$0	$413,000	$0	$0	$0
MICHAEL CHARLES ZODY
SCIENTIFIC DIR, COMP BIOLOGY	$350,538	$0	$0	$0	$0	$0	$18,300	$0	$9,031	$0	$377,869	$0	$0	$0
CHARLES GAGNON
CHIEF INFORMATION OFFICER	$326,038	$0	$0	$0	$3,942	$0	$16,981	$0	$30,450	$0	$377,411	$0	$0	$0
SHAILAJA GARGEYA
SENIOR DIR, SOFTWARE ENGINEER	$320,347	$0	$0	$0	$0	$0	$18,195	$0	$117	$0	$338,659	$0	$0	$0
DAYNA M OSCHWALD
CHIEF OF STAFF	$268,319	$0	$0	$0	$0	$0	$15,825	$0	$19,856	$0	$304,000	$0	$0	$0
CHRISTOPHER PHIFER BLACK
SENIOR DIRECTOR, RESEARCH COMPUTING	$244,736	$0	$0	$0	$0	$0	$15,098	$0	$27,700	$0	$287,534	$0	$0	$0
HANNAH GOULDING
SENIOR DIRECTOR, HUMAN RESOURCES	$235,875	$0	$0	$0	$0	$0	$14,152	$0	$117	$0	$250,144	$0	$0	$0
JESSICA LEIGH LEITNER
SENIOR DIRECTOR, DEVELOPMENT	$227,847	$0	$0	$0	$0	$0	$13,739	$0	$8,078	$0	$249,664	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 3	FormAndLineReferenceDesc
Explanation	IN 2022, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION AND AS A SENIOR ASSOCIATE MEMBER OF NYGC'S FACULTY. HE OVERSAW NYGC'S RESEARCH PROGRAM AND UNDERTOOK OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. IN 2022, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE SCIENTIFIC DIRECTOR & CEO, WAS REASONABLE.	ExplanationTxt

Schedule L IRS990ScheduleL

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

Field	Value	IRS element (for citing)
Person	SILAS MANIATIS	PersonNm

Field	Value	IRS element (for citing)
Relationship Description	FAMILY MEMBER	RelationshipDescriptionTxt
Transaction	$195,148	TransactionAmt
Transaction	SALARY+BENEFITS	TransactionDesc
Sharing Of Revenues	0	SharingOfRevenuesInd

Schedule M IRS990ScheduleM

Other Non Cash Contri Table OtherNonCashContriTableGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Desc	RESEARCH SUPPLIES	Desc
Contribution	199	ContributionCnt
Noncash Contributions Rpt F990	$2,153,885	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	0	ReviewProcessUnusualNCGiftsInd
Third Parties Used	0	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, COLUMN (B):	FormAndLineReferenceDesc
Explanation	THE NUMBER REPORTED IN PART I, COLUMN B REPRESENTS THE NUMBER OF UNITS CONTRIBUTED.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (12 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART I, LINE 1 & PART III, LINE 1:	THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT NON-PROFIT SCIENTIFIC RESEARCH INSTITUTION DEDICATED TO COLLABORATIVE GENETIC AND GENOMIC RESEARCH. NYGC'S MISSION IS TO ADVANCE GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVE NOVEL BIOMEDICAL DISCOVERIES. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF COMPUTATIONAL AND EXPERIMENTAL GENOMIC METHODS AND DISEASE-FOCUSED RESEARCH TO BETTER UNDERSTAND THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE AND NEUROPSYCHIATRIC DISEASE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO TOM MANIATIS, PHD, INCLUDES ASSOCIATE AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE CENTER BRINGS TOGETHER OUTSTANDING THOUGHT LEADERS FROM ELEVEN INSTITUTIONAL FOUNDING MEMBERS, SIX ASSOCIATE MEMBER INSTITUTIONS, AND 87 AFFILIATE SCIENTIFIC MEMBERS TO ENGAGE IN COLLABORATIVE RESEARCH. CONVENING TALENT AND EXPERTISE FROM MULTIPLE TOP-TIER SCIENTIFIC AND MEDICAL INSTITUTIONS IN THE NEW YORK AREA AND BEYOND, WE HAVE CREATED A HIGHLY COLLABORATIVE SCIENTIFIC ECOSYSTEM AND COMMUNITY RESOURCE THAT IS MORE THAN THE SUM OF ITS PARTS. NYGC ALSO PROVIDES RESEARCHERS WITH ACCESS TO STATE-OF-THE-ART GENOMIC INFRASTRUCTURE (E.G., COMPUTER HARDWARE AND SOFTWARE, SEQUENCING INSTRUMENTS) AND TECHNOLOGY INNOVATION AND EXPERTISE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) LEADING AND CONTRIBUTING TO INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD. (II) RECRUITING AND RETAINING DIVERSE WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE ORGANIZATION'S RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAMS; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGC'S SCIENTIFIC RESEARCH MISSION; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATION'S FACILITY, FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) IMPROVING HUMAN HEALTH THROUGH GENOMIC RESEARCH THAT DRIVES NOVEL BIOMEDICAL DISCOVERIES; (VI) STRIVING TO MAXIMIZE THE BENEFITS OF OUR RESEARCH AND INNOVATION FOR DIVERSE COMMUNITIES; (VII) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; (VIII) CREATING A WORKPLACE ENVIRONMENT THAT IS WELCOMING AND FAIR TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL DISABILITY, AGE, OR RELIGION, AND (IX) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. NYGC STRIVES TO CHAMPION DIVERSITY, EQUITY, AND INCLUSION IN ITS WORKPLACE AND IN THE APPLICATION OF ITS RESEARCH TO CLINICAL CARE. A FUNDAMENTAL GOAL OF THE GENOME CENTER IS ADDRESSING THE LACK OF DIVERSITY WITHIN DATA, SAMPLES, AND SUBJECTS IN GENOMICS RESEARCH. NYGC IS ALSO COMMITTED TO DIVERSITY ON THE CENTER'S BOARD OF DIRECTORS AND WITHIN ITS FACULTY, STAFF, AND SCIENTIFIC RESEARCHERS.
FORM 990, PART III, LINE 4A & LINE 4B	THE NEW YORK GENOME CENTER (NYGC) IS COMMITTED TO ADVANCING GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVING THE DEVELOPMENT OF NOVEL BIOMEDICAL THERAPEUTICS FOR CLINICAL CARE. RESEARCH AND FACULTY CENTRAL TO THE SUCCESS OF NYGC IS OUR TALENTED FACULTY WHO POSE FUNDAMENTAL QUESTIONS, DEVELOP NOVEL APPROACHES TO SCIENTIFIC INQUIRY, AND DEEPLY PROBE THE BIOLOGICAL MECHANISMS RELEVANT TO HUMAN HEALTH AND DISEASE. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. IN 2022, WE INCREASED THE SIZE AND BROADENED THE EXPERTISE OF OUR FACULTY, A STRATEGIC STEP FORWARD. WITH THESE NEW APPOINTMENTS, WE ADDED DEPTH, BREADTH, AND SCOPE TO THE GENOME CENTER'S OVERALL RESEARCH PROGRAM. THE NEW MEMBERS INCLUDE: - GAMZE GRSOY, PHD., AN EXPERT IN THE DEVELOPMENT AND APPLICATION OF NOVEL TOOLS FOR PRESERVING PRIVACY IN LARGE GENOMIC DATASETS AS WELL AS THE RELATIONSHIP BETWEEN GENOMES AND MOLECULAR MEASUREMENTS IN RELATION TO DISEASES - SANJA VICKOVI, PHD, AN ACCOMPLISHED TECHNOLOGIST AND ENGINEER FOCUSED ON DEVELOPING NOVEL TOOLS FOR SPATIAL GENOMICS - CHENXU ZHU, PHD, A DEVELOPER OF INNOVATIVE MULTIMODAL SINGLE-CELL GENOMIC TOOLS - TARJINDER SINGH, PHD, WHO JOINED US AS AN ASSOCIATE FACULTY MEMBER, IS A NEUROPSYCHIATRIC DISEASE RESEARCHER FOCUSED ON IDENTIFYING GENOMIC MARKERS THAT UNDERLIE THE CAUSES OF PSYCHIATRIC DISEASE. IN 2022, NYGC SCIENTISTS MADE CONTINUING CONTRIBUTIONS TO PIONEERING RESEARCH INCLUDING: - NYGC CORE FACULTY MEMBER NEVILLE SANJANA, PHD, WHO HOLDS A JOINT APPOINTMENT AT NEW YORK UNIVERSITY (NYU) AS AN ASSOCIATE PROFESSOR OF BIOLOGY WITH TENURE, DISCOVERED SYNTHETIC GENE PROGRAMS THAT PROFOUNDLY REWIRE T CELLS, MAKING THEM MORE EFFECTIVE AT FINDING AND FIGHTING CANCER CELLS. THE GOAL OF THIS LARGE-SCALE GENETIC SCREEN WAS TO IDENTIFY PRECISELY THOSE GENES THAT ENABLE T CELLS TO PROLIFERATE AND TO UNDERSTAND HOW THOSE GENES IMPACT OTHER ASPECTS OF IMMUNE CELL FUNCTION RELEVANT TO FIGHTING CANCER. - NYGC'S SCIENTIFIC DIRECTOR FOR COMPUTATIONAL BIOLOGY, MICHAEL ZODY, PHD, AND HIS TEAM, IN COLLABORATION WITH GROUPS AT THE MASSACHUSETTS GENERAL HOSPITAL, YALE UNIVERSITY, AND THE HUMAN GENOME STRUCTURAL VARIATION CONSORTIUM (HGSVC), EXPANDED THE 1000 GENOMES PROJECT (1KGP) RESOURCE TO INCLUDE NEARLY ALL PARENT-CHILD TRIOS IN THE COLLECTION, ALONGSIDE THE ORIGINAL SAMPLES, AND SEQUENCED THEM AT HIGH COVERAGE USING ILLUMINA NOVASEQ INSTRUMENTS. THE STUDY, PRESENTS COMPREHENSIVE ANALYSES OF THE HIGH-COVERAGE WHOLE GENOME SEQUENCING DATA ON THE EXPANDED 1KGP COHORT WHICH NOW CONSISTS OF 3,202 SAMPLES, INCLUDING 602 TRIOS. - DAVID KNOWLES, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, IN COLLABORATION WITH INVESTIGATORS AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, RECEIVED AN AWARD IN THE AMOUNT OF $2.7M FROM THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) ENTITLED "DELINEATING THE NETWORK EFFECTS OF MENTAL DISORDER-ASSOCIATED VARIANTS USING CONVEX OPTIMIZATION METHODS". THE AIM OF THIS GRANT IS TO DEVELOP A SUITE OF NOVEL COMPUTATIONAL METHODS TO DETERMINE THE SHARED AND DISTINCT GENETIC COMPONENTS OF NEUROPSYCHIATRIC DISORDERS, INFER THE CAUSAL GENE NETWORKS UNDERLYING THESE COMPONENTS, AND MODEL HOW COMMON AND RARE GENETIC VARIANTS DISRUPT THESE NETWORKS. - CORE FACULTY MEMBER, MARCIN IMIELISKI, MD, PHD, WHO HOLDS A JOINT APPOINTMENT AT WEILL CORNELL MEDICINE, COLLABORATED WITH OXFORD NANOPORE TECHNOLOGIES TO DEVELOP A NEW METHOD OF ASSESSING THE THREE-DIMENSIONAL STRUCTURE OF THE HUMAN GENOME, OR HOW THE GENOME FOLDS, ON A LARGE SCALE. - NYGC'S CATHERINE REEVES, GIUSEPPE NARZISI, PHD, SOREN GERMER, PHD, MELISSA MARTON, NICOLAS ROBINE, PHD, LARA WINTERKORN, CHARLES GAGNON, AND MINITA SHAH RECEIVED AN AWARD IN THE AMOUNT OF $2.17M FROM THE NATIONAL CANCER INSTITUTE TO OPERATE A GENOMIC CHARACTERIZATION CENTER FOR TWO NEW STUDIES INVESTIGATING ENDOMETRIAL CANCER AND NASOPHARYNGEAL CARCINOMA, PROVIDING EXCEPTIONALLY HIGH QUALITY, COMPREHENSIVE, AND TIMELY GENOME-WIDE CHARACTERIZATION OF NUCLEIC ACID SAMPLES OBTAINED FROM CANCER PATIENTS IN ORDER TO IDENTIFY AND PROVIDE ANNOTATION FOR GENOMIC ALTERATIONS. - GAMZE GRSOY, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, RECEIVED THE R35 MAXIMIZING INVESTIGATORS' RESEARCH AWARD FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES FOR A PROJECT ENTITLED "TOOLS TO ADDRESS THE CHALLENGES OF PRESERVING PRIVACY IN SHARING AND ANALYSIS OF BIOMEDICAL DATA." THE GOAL OF THIS PROJECT IS TO QUANTIFY PRIVATE INFORMATION LEAKAGES FROM VARIOUS TYPES OF HUMAN-DERIVED BIOLOGICAL DATA AND TO DEVELOP PRIVACY-ENHANCING ANALYSIS SOFTWARE FOR DATA AT VARIOUS MOLECULAR LEVELS (GENOMICS, TRANSCRIPTOMICS, PHENOTYPE, AND CLINICAL DATA) AT SCALE. - CHENXU ZHU, PHD, WHO HOLDS A JOINT APPOINTMENT AT WEILL CORNELL MEDICINE, RECEIVED AN AWARD IN THE AMOUNT OF $513,842 FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE TO FURTHER EXPAND THE SCALABILITY AND SPECTRUM FOR SINGLE CELL MULTI-MODAL GENOMIC ANALYSIS AND APPLY THESE TOOLS IN THE STUDY OF THE FUNCTION AND RELATIONSHIPS OF MULTIPLE REGULATORY LAYERS DURING MAMMALIAN DEVELOPMENT PROCESSES. - HEMALI PHATNANI, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, RECEIVED AN AWARD FROM TARGET ALS FOR A PROJECT ON "SCALABLE PHENOTYPING OF ALS-ASSOCIATED POINT MUTATIONS, USING BASE EDITOR POOLED GENOMIC SCREENS AND A SINGLE CELL TRANSCRIPTOMIC READOUT." THE GOAL IS TO GENERATE DATA USING THE 4I PLATFORM THAT WILL EXTEND SPATIALLY RESOLVED TRANSCRIPTOME ANALYSES FOR AN UNBIASED, GENOME-WIDE VIEW OF CELL TYPE DEPENDENT CHANGES OVER THE COURSE OF DISEASE. - VAIDEHI JOBANPUTRA, PHD, FACMG, CHIEF DIAGNOSTICS OFFICER AT NYGC, PARTICIPATED IN A PANEL ON THE IMPLEMENTATION OF WHOLE-GENOME AND TRANSCRIPTOME SEQUENCING (WGTS) IN ROUTINE CANCER CARE AND DIAGNOSTICS. SHE JOINED TWENTY-FOUR GLOBAL EXPERTS IN ONCOLOGY, PATHOLOGY, GENETICS, TRANSLATIONAL RESEARCH, AND HEALTH TECHNOLOGY ASSESSMENT TO DISCUSS GENERAL AND TECHNICAL ASPECTS, HEALTH ECONOMICS AND REIMBURSEMENT, AND CLINICAL EVIDENCE NEEDS, AS WELL AS DATA ANALYSIS AND INTERPRETATION IN RELATION TO WGTS. ADDITIONAL ACCOMPLISHMENTS IN 2022 INCLUDE: IN 2022, NYGC MADE GREAT PROGRESS IN CORE RESEARCH AREAS UNDER THE LEADERSHIP OF THE NEW YORK GENOME CENTER'S EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS, PHD. NYGC FACULTY AND SCIENTIFIC STAFF PUBLISHED 46 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS THAT PROVIDED NEW GENOMIC APPROACHES AND TECHNOLOGIES AS WELL AS INSIGHTS INTO THE GENOMICS OF BIOLOGY AND DISEASE. NYGC RESEARCHERS HAVE DEVELOPED MANY INNOVATIVE GENOMIC TECHNOLOGIES AND NEW COMPUTATIONAL APPROACHES THAT ARE SHARED AND BROADLY ADOPTED WITHIN THE SCIENTIFIC COMMUNITY. CANCER: THE MACMILLAN FAMILY FOUNDATION, A FIRST-TIME DONOR MADE A SIGNIFICANT INVESTMENT IN 2022 TO CREATE THE MACMILLAN CENTER FOR THE STUDY OF THE NON-CODING CANCER GENOME. HIGHLIGHTING THE CENTER'S EXPERIENCE AND CAPACITY FOR COLLABORATION, OUR RESEARCHERS PROPOSED A BOLD SCIENTIFIC VISION FOCUSED ON UNDERSTANDING THE ROLE AND FUNCTION OF THE NON-CODING GENOME AND EPIGENOME IN CANCER EVOLUTION, PROGRESSION, AND TREATMENT RESPONSE. THE GENOME CENTER CANCER GROUP (GCCG), LED BY NOBEL LAUREATE HAROLD VARMUS, MD, NYGC AND WEILL CORNELL MEDICINE, AND HHMI INVESTIGATOR CHARLES SAWYERS, MD, MEMORIAL SLOAN KETTERING CANCER CENTER, IS COMPOSED OF CLINICIANS AND CANCER RESEARCHERS FROM NYGC'S MEMBER INSTITUTIONS, INCLUDING 10 NCI-DESIGNATED CANCER CENTERS. NYGC'S COLLABORATIVE CANCER INITIATIVE, POLYETHNIC-1000 (P-1000), WAS LAUNCHED IN 2018 TO ADVANCE CANCER GENOMICS IN UNDERREPRESENTED POPULATIONS. IN THE PAST YEAR, MELISSA B. DAVIS, PHD, ETHNICITY AND CANCER SCHOLAR FOR THE P-1000 INITIATIVE AND ASSOCIATE PROFESSOR OF CELL AND DEVELOPMENTAL BIOLOGY RESEARCH IN SURGERY AND DIRECTOR OF HEALTH EQUITY IN THE ENGLANDER INSTITUTE FOR PRECISION MEDICINE AT WEILL CORNELL MEDICINE PUBLISHED A STUDY ON THE BIOLOGICAL LINKS BETWEEN AFRICAN ANCESTRY AND DISEASE PROCESSES THAT AFFECT AN AGGRESSIVE CANCER TYPE CALLED TRIPLE-NEGATIVE BREAST CANCER (TNBC). THE RESEARCHERS' ANALYSIS OF TNBC TUMORS YIELDED A LARGE SET OF GENES WHOSE EXPRESSION DIFFERED IN PATIENTS WITH AFRICAN ANCESTRY COMPARED TO PATIENTS WITH EUROPEAN ANCESTRY. THE STUDY ALSO DESCRIBES DISTINCT PATTERNS OF IMMUNE RESPONSES IN PATIENTS WITH AFRICAN DESCENT THAT MAY EXPLAIN PATTERNS OF DISEASE PROGRESSION AND OUTCOMES, THUS ALTERING THE BENEFITS OF IMMUNOTHERAPIES.
FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED)	NEURODEGENERATIVE DISEASE: NYGC'S CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), LED BY DIRECTOR HEMALI PHATNANI, PHD, IS A GLOBAL COLLABORATION OF CLINICIANS, SCIENTISTS, GENETICISTS, AND COMPUTATIONAL BIOLOGISTS THAT CONTINUES TO MAKE GREAT STRIDES. THE NYGC ALS CONSORTIUM, LAUNCHED BY THE CGND IN 2016, IS DEDICATED TO THE GENERATION OF ONE OF THE LARGEST OPEN-SOURCE WHOLE GENOME SEQUENCING DATABASES OF ALS PATIENTS IN THE UNITED STATES. THIS CONSORTIUM HAS BROUGHT TOGETHER THE INTERNATIONAL ALS COMMUNITY, INCLUDING PROJECT ALS AND ANSWER ALS INITIATIVES, TO TAKE ADVANTAGE OF INTEGRATED DATASETS AND DEPLOY A WIDE ARRAY OF APPROACHES TO ALS RESEARCH WITH THE ULTIMATE GOAL OF UNDERSTANDING DISEASE PROGRESSION, IMPROVING DIAGNOSIS AND EARLY DETECTION, AND IDENTIFYING NEW TARGETS FOR THERAPEUTIC AND PREVENTATIVE INTERVENTIONS. THE WHOLE GENOME DATABASE WILL MERGE WITH A LARGE NIH DATABASE WITH OTHER TYPES OF GENOMIC DATA AND SERVE AS A LASTING RESOURCE FOR THE INTERNATIONAL ALS COMMUNITY, INCLUDING CONTINUED COLLABORATIVE RESEARCH THROUGH THE CONSORTIUM. NEUROPSYCHIATRIC DISEASE: DR. THOMAS LEHNER, NYGC'S SCIENTIFIC DIRECTOR FOR NEUROPSYCHIATRIC DISEASE, LEADS NYGC'S NEUROPSYCHIATRIC DISEASE SCIENTIFIC WORKING GROUP. ONE OF THE SIGNATURE INITIATIVES OF THIS GROUP IS GEMMA (GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT), A NEW YORK STATE-WIDE PRECISION PSYCHIATRY COLLABORATION THAT AIMS TO INTEGRATE DIAGNOSTIC, DEMOGRAPHIC, AND MEDICAL RECORDS DATA WITH GENOMIC DATA TO CREATE A PLATFORM FOR SCIENTIFIC DISCOVERY, CLINICAL VALIDATION, AND TRANSLATIONAL IMPLEMENTATION. THIS RESOURCE WOULD IMPROVE THE QUALITY OF LIFE, SOCIAL EQUITY, AND OUTCOMES OF INDIVIDUALS WITH SERIOUS MENTAL ILLNESS IN NEW YORK. ADDITIONALLY, NYGC IS ADVANCING ITS CLINICAL OUTCOME PREDICTION OF PSYCHOSIS FROM EHRS (COPPER), A PILOT STUDY LEVERAGING THE GEMMA PLATFORM FOCUSED ON ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING, TO BUILD MODELS OF CLINICAL PREDICTORS OF DIAGNOSIS, TREATMENT, AND PROGNOSIS OF PSYCHOSIS-RELATED DISORDERS. IN PRECISION PSYCHIATRY, THE NYGC TEAM PLANS TO INTEGRATE LARGE-SCALE LONGITUDINAL ELECTRONIC HEALTH RECORDS, DIMENSIONAL PHENOTYPING, AND GENETIC ANALYSES TO IMPROVE CLINICAL PREDICTORS OF SERIOUS MENTAL ILLNESS. IN DECEMBER 2022, DR. LEHNER AND NEW ASSOCIATE FACULTY MEMBER, DR. TARJINDER SINGH, RECEIVED PHILANTHROPIC FUNDING TO LAUNCH A NEW PROJECT TO CARRY OUT WHOLE GENOME SEQUENCING AND BIOINFORMATIC ANALYSIS ON A WELL-CHARACTERIZED COHORT OF PATIENTS WITH SEVERE SCHIZOPHRENIA. IN A COLLABORATION WITH DR. CARLOS PATO AT RUTGERS UNIVERSITY AND LEVERAGING NEW REDUCED-COST SEQUENCING PLATFORMS, NYGC WILL SEQUENCE AND ANALYZE A COHORT OF 2,500 PATIENTS WITH SEVERE SCHIZOPHRENIA FROM THE RUTGERS GENOMIC PSYCHIATRY COHORT TO IDENTIFY POTENTIALLY CAUSATIVE GENETIC VARIANTS. RESEARCHERS WILL ALSO BE ABLE TO USE CELL LINES DERIVED FROM EACH PARTICIPANT IN THE COHORT TO INVESTIGATE THE UNDERLYING CAUSATIVE DISEASE MECHANISMS. THE RESEARCH TEAM PLANS TO INTEGRATE THE WHOLE GENOME SEQUENCE DATA WITH EXISTING LARGE-SCALE DATASETS, CONTROLS, AND INTERNATIONAL DISCOVERY EFFORTS TO ADVANCE PRECISION MEDICINE IN PSYCHIATRY. THIS YEAR, DRS. LEHNER AND SINGH ALONG WITH SCIENTIFIC DIRECTOR OF COMPUTATIONAL BIOLOGY, DR. MICHAEL ZODY, HAVE SUBMITTED A GRANT PROPOSAL IN COLLABORATION WITH THE BROAD INSTITUTE OF MIT AND HARVARD TO BREAKTHROUGH DISCOVERIES FOR THRIVING WITH BIPOLAR DISORDER (BD2) TO LAUNCH THE BIPOLAR DISORDER SEQUENCING AND GENE DISCOVERY INITIATIVE. THE PROJECT AIMS TO ASSEMBLE A SEQUENCED COHORT OF ~100,000 ANCESTRALLY DIVERSE INDIVIDUALS LIVING WITH BIPOLAR DISORDER (BD) WITH MATCHED CONTROL SAMPLES TO IDENTIFY RISK GENES FOR BD, UNCOVER THE BIOLOGICAL MECHANISMS UNDERLYING ITS PATHOBIOLOGY, AND CATALYZE THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES. GENOMIC TECHNOLOGY: THE NYGC TECHNOLOGY INNOVATION LAB HAS ESTABLISHED ITSELF AS A LEADER AT THE FOREFRONT OF GENOMIC SCIENCE AND TECHNOLOGY, CURRENTLY CENTERED ON THE INVENTION OF NEW CELLULAR, SUBCELLULAR AND SPATIALLY RESOLVED MEASUREMENT METHODS WITH IMPROVED THROUGHPUT, RESOLUTION, SENSITIVITY, ACCURACY, AND COST EFFICIENCY. MORE RECENTLY, THE LAB IS ALSO FOCUSED ON COMBINATIONS OF MEASUREMENTS IN THE SAME CELL SYSTEMS (OR "MULTIMODALITY") WITH ACCOMPANYING MATHEMATICAL AND STATISTICAL ADVANCES. THE INNOVATION LAB, UNDER THE LEADERSHIP OF SANJA VICKOVI, PHD AND IN COLLABORATION WITH NYGC FACULTY AS WELL AS OTHER ACADEMIC AND INDUSTRY PARTNERS, HAS CONTINUED TO DEVELOP AND APPLY GROUNDBREAKING GENOMIC TECHNOLOGIES IN THIS SPACE AND MAKING THEM BROADLY AVAILABLE TO THE SCIENTIFIC COMMUNITY. DR. VICKOVI IS AN EXPERIENCED AND ACCOMPLISHED ENGINEER WHO DEVELOPS TOOLS FOR SPATIAL GENOMICS THAT ENABLE PERTURBING HIGHLY COMPLEX INTERACTIONS IN HUMAN TISSUES, MANY OF WHICH ARE NOW COMMERCIALIZED. THE GENOME CENTER'S TECHNOLOGY INNOVATION LAB ALSO IS AN INTERNATIONALLY-RECOGNIZED PIONEER IN "SINGLE CELL" GENOMIC TECHNOLOGY,, AND COLLABORATES CLOSELY WITH NYGC CORE FACULTY MEMBER DR. RAHUL SATIJA TO DEVELOP COMPUTATIONAL TOOLS FOR DECODING SINGLE-CELL DATA WHICH HAVE "DEMOCRATIZED" SINGLE-CELL DATA ANALYSIS. THESE ADVANCES HAVE MADE IT POSSIBLE FOR SCIENTISTS WITH LITTLE MATHEMATICAL EXPERTISE TO TAKE ADVANTAGE OF SINGLE-CELL TECHNOLOGIES AND APPLY THEM TO A BROAD RANGE OF SCIENTIFIC INQUIRY. ADDITIONALLY, THE CENTER FOR INTEGRATED CELLULAR ANALYSIS (CICA): SINGLE CELL AND SPATIAL MULTI-OMICS, LED BY DR. SATIJA, REPRESENTS A COLLABORATIVE EFFORT BETWEEN TECHNOLOGY DEVELOPERS, COMPUTATIONAL BIOLOGISTS, NEUROSCIENTISTS, AND CANCER BIOLOGISTS FROM SEVEN NYC-BASED INSTITUTIONS TO DEVELOP TECHNOLOGIES FOR NOVEL SINGLE-CELL ANALYSES IN VARIOUS BIOLOGICAL CONTEXTS AND DISEASE STATES. CLINICAL LABORATORY: NYGC'S CLINICAL LABORATORY HAS LENT ITS INFRASTRUCTURE AND EXPERTISE TO SEVERAL LARGE-SCALE INITIATIVES IN CLINICAL GENOMICS, INCLUDING A COLLABORATION WITH WEILL CORNELL MEDICINE, NEWYORK-PRESBYTERIAN HOSPITAL, AND ILLUMINA ON A PRECISION MEDICINE COLLABORATION IN CANCER, CARDIOLOGY, ENDOCRINOLOGY, AND NEUROLOGY TO ASSESS AND IMPROVE THE VALUE OF CLINICAL WHOLE GENOMES WITH AIMS OF RETURNING CLINICALLY ACTIONABLE RESULTS, INTEGRATING ELECTRONIC HEALTH RECORDS, DEVELOPING NOVEL POLYGENIC RISK SCORES, AND GAINING A DEEPER UNDERSTANDING OF THE ROLE OF GENETICS IN THERAPEUTIC RESPONSES. FINALLY THE CLINICAL LABORATORY INITIATED A COLLABORATION WITH THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY AT COLUMBIA UNIVERSITY: THE WOMENS' GENETICS CENTER (WGC). THE WGC BUILDS ON THE COMBINED STRENGTH OF THE UNIVERSITY'S MATERNAL FETAL MEDICINE PHYSICIANS AND GENETIC COUNSELORS AND NYGC'S EXPERTISE IN TECHNOLOGY AND CLINICAL GENETICS TO DEVELOP AND APPLY NOVEL CLINICAL TESTS TO ADVANCE CARE FOR PREGNANT WOMEN. THE CLINICAL LABORATORY PERFORMED THE FIRST 15 WHOLE GENOME SEQUENCING PRENATAL TESTS TO DISCOVER THE GENETIC CAUSES OF ANOMALIES OBSERVED WITH ULTRASOUND, AND BEGAN PLANNING FOR THE DEVELOPMENT OF ADDITIONAL NOVEL CLINICALLY RELEVANT WHOLE GENOME BASED TESTS. RESEARCH SEQUENCING NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SEVEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 86,900 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE THOUSANDS OF GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 20,000 SAMPLES IN 2022, INCLUDING 7,640 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), 6,092 COVID VIRAL SAMPLES, AND 6,520 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. IN ADDITION THE LAB PERFORMED 14,082 RNA EXTRACTIONS, IN PART FOR OTHER LABORATORIES THAT EITHER DID NOT HAVE THE CAPACITY OR WERE NOT ABLE TO GENERATE RNA OF SUFFICIENT QUALITY. THE NYGC RESEARCH SEQUENCING LAB ALSO RECEIVED, TESTED AND OPERATIONALIZED THE TWO NEW SEQUENCING INSTRUMENTS PURCHASED IN 2021, AND BEGAN TO PROCESS SAMPLES FOR COLLABORATIVE PROJECTS USING THE INSTRUMENTS. ONE INSTRUMENT, FROM OXFORD NANOPORE TECHNOLOGIES, ADDS LONG READ CAPACITY TO THE CENTER'S SEQUENCING MENU, THE OTHER SEQUENCING INSTRUMENT, FROM ULTIMA GENOMICS,PROMISES SUBSTANTIALLY REDUCED REAGENT COSTS FOR HIGH-THROUGHPUT APPLICATIONS AND HAS CREATED A LOT OF EXCITEMENT IN THE GENOMICS COMMUNITY. FOR BOTH INSTRUMENTS, NYGC IS WORKING INTENSIVELY TO ENABLE THESE TECHNOLOGIES FOR A RANGE OF APPLICATIONS.
FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED)	IN 2022, NYGC CONTINUED TO EXPAND ITS OPERATIONAL FOCUS ON SINGLE-CELL GENOMICS, MAKING AVAILABLE TO THE RESEARCH COMMUNITY THROUGH FUNCTIONAL GENOMIC COLLABORATIONS NEW CUTTING-EDGE TECHNIQUES INVENTED IN THE CENTER'S INNOVATION LAB. THESE INCLUDE CITE-SEQ, ASAP-SEQ, AND DOGMA-SEQ AS WELL AS THE 10X MULTIOME ASSAY, TECHNIQUES THAT ALLOW SIMULTANEOUS MEASUREMENT IN THOUSANDS OF CELLS COMBINATIONS OF CELL SURFACE PROTEIN MARKERS, RNA ABUNDANCE AND CHROMATIN ACCESSIBILITY. THE CENTER'S TECHNOLOGY INNOVATION LABORATORY HAS COMPLETED SEVERAL PROJECTS AND IS GEARING UP TO SUPPORT MULTIPLE LARGE GRANTS IN WHICH THESE ASSAYS WILL BE APPLIED. IN ADDITION, THE LAB HAS IMPLEMENTED A NOVEL AMPLIFICATION FREE SINGLE CELL WHOLE GENOME SEQUENCING ASSAY THAT IS BEING USED IN A LARGE STUDY OF ESOPHAGEAL CANCER IN A COLLABORATION WITH COLUMBIA UNIVERSITY AND CAMBRIDGE UNIVERSITY. DIVERSITY, EQUITY, AND INCLUSION IN 2020, NYGC LAUNCHED AN ORGANIZATION-WIDE DIVERSITY, EQUITY, AND INCLUSION ("DEI") INITIATIVE, AFFIRMING NYGC'S COMMITMENT TO TAKE ACTIONABLE STEPS TOWARD FOSTERING A COMMUNITY ENVIRONMENT THAT IS WELCOMING AND INCLUSIVE TO ALL. EACH EMPLOYEE HAS THE RIGHT TO BE TREATED WITH DIGNITY AND RESPECT OF INDIVIDUAL DIFFERENCES. IN 2022, NYGC'S CROSS-FUNCTIONAL DEI ADVISORY GROUP PROVIDED EDUCATION AND RESOURCES TO THE NYGC COMMUNITY TO RAISE AWARENESS OF DEI AND TO ENHANCE CULTURAL COMPETENCY, SUCH AS BOOK CLUBS, SHOWCASING THE WORK AND SKILLS OF A DIVERSE GROUP OF EMPLOYEES, STAFF, FACULTY AND TRAINEES, AND ORGANIZED DEI-RELATED EVENTS. THE CENTER ALSO BEGAN A SEARCH FOR A DIRECTOR OF DEI TO SPEARHEAD EXISTING AND EXPANDED DEI EFFORTS.
FORM 990, PART VI, SECTION A, LINE 4	IN MARCH, 2022, NYGC'S BOARD OF DIRECTORS AMENDED THE CORPORATION'S BYLAWS TO DIVIDE THE BOARD'S INDEPENDENT MEMBERS INTO THREE GROUPS WITH STAGGERED TERMS. THE TERM OF ALL DIRECTORS IN A GIVEN GROUP NOW EXPIRES IN THE SAME YEAR, ELIMINATING THE NEED TO TRACK EACH DIRECTOR'S TERM ON AN INDIVIDUAL BASIS. IN ADDITION, THE BOARD APPROVED A SECOND AMENDMENT TO REDUCE THE BOARD'S STANDING COMMITTEES FROM SIX TO FOUR (EXECUTIVE, AUDIT, COMPENSATION, DEVELOPMENT AND NOMINATING). THE GOAL OF THIS CHANGE WAS TO BETTER ALIGN THE NUMBER OF STANDING COMMITTEES TO THE SIZE OF THE BOARD, ELIMINATE OVERLAPPING COMMITTEE RESPONSIBILITIES, AND ENHANCE THE OVERALL FUNCTIONALITY AND PRODUCTIVITY OF BOARD COMMITTEES.
FORM 990, PART VI, SECTION A, LINE 6	ORGANIZATION MEMBERS AS OF DECEMBER 31, 2022, THE CENTER HAD A TOTAL OF 17 MEMBERS, CONSISTING OF 11 INSTITUTIONAL FOUNDING MEMBERS AND SIX ASSOCIATE MEMBERS. THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) MEMORIAL SLOAN-KETTERING CANCER CENTER, (4) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (5) NEW YORK-PRESBYTERIAN HOSPITAL, (6) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (7) NORTHWELL HEALTH, (8) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (9) THE ROCKEFELLER UNIVERSITY, (10) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (11) ALBERT EINSTEIN COLLEGE OF MEDICINE. ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, (4) HACKENSACK MERIDIAN HEALTH, (5) GEORGETOWN LOMBARDI COMPREHENSIVE CANCER CENTER, AND (6) RUTGERS CANCER INSTITUTE OF NEW JERSEY.
FORM 990, PART VI, SECTION A, LINE 7A	ORGANIZATION MEMBERS - DECISION MAKING EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL.
FORM 990, PART VI, SECTION B, LINE 11B	FORM 990 REVIEW THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND THE SCIENTIFIC DIRECTOR/CEO REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS.
FORM 990, PART VI, SECTION B, LINE 12C	CONFLICT OF INTEREST POLICY & REVIEW NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST.
FORM 990, PART VI, SECTION B, LINE 15	COMPENSATION REVIEW AND APPROVAL FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2022, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT WAS REASONABLE. THE COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET AT A COMMITTEE MEETING HELD IN FEBRUARY 2022 AND APPROVED THE 2022 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. THE SENIOR MANAGEMENT TEAM RECEIVED STANDARD MERIT INCREASES IN 2022.
FORM 990, PART VI, SECTION C, LINE 19	NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.
FORM 990, PART VII, SECTION A	IN 2022, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS.